Grunenthal Submits European Marketing Authorisation Application For Centrally Acting Analgesic Tapentadol

German pain expert Grunenthal GmbH announced that it has submitted the Marketing Authorisation Application (MAA) for tapentadol prolonged- and immediate-release (PR/IR) tablets to several European authorities including BfArM (Germany) who will act as Reference Member State for the Decentralised Procedure (DCP). Grunenthal is seeking an indication for the treatment of severe acute and severe chronic pain requiring centrally acting analgesics therapy in adults 18 years and older.

More: continued here

Filed under: Pain / Anesthetics on May 11th, 2009